{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:23:22Z","timestamp":1787027002035,"version":"build-2736575974"},"reference-count":132,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T00:00:00Z","timestamp":1609804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Sickle cell disease (SCD) is a severe autosomal recessively inherited disorder of the red blood cell characterized by erythrocyte deformation caused by the polymerization of the abnormal hemoglobin, which leads to erythrocyte deformation and triggers downstream pathological changes. These include abnormal rheology, vaso-occlusion, ischemic tissue damage, and hemolysis-associated endothelial dysfunction. These acute and chronic physiologic disturbances contribute to morbidity, organ dysfunction, and diminished survival. Hematopoietic cell transplantation (HCT) from HLA-matched or unrelated donors or haploidentical related donors or genetically modified autologous hematopoietic progenitor cells is performed with the intent of cure or long-term amelioration of disease manifestations. Excellent outcomes have been observed following HLA-identical matched related donor HCT. The majority of SCD patients do not have an available HLA-identical sibling donor. Increasingly, however, they have the option of undergoing HCT from unrelated HLA matched or related haploidentical donors. The preliminary results of transplantation of autologous hematopoietic progenitor cells genetically modified by adding a non-sickling gene or by genomic editing to increase expression of fetal hemoglobin are encouraging. These approaches are being evaluated in early-phase clinical trials. In performing HCT in patients with SCD, careful consideration must be given to patient and donor selection, conditioning and graft-vs.-host disease regimen, and pre-HCT evaluation and management during and after HCT. Sociodemographic factors may also impact awareness of and access to HCT. Further, there is a substantial decisional dilemma in HCT with complex tradeoffs between the possibility of amelioration of disease manifestations and early or late complications of HCT. The performance of HCT for SCD requires careful multidisciplinary collaboration and shared decision making between the physician and informed patients and caregivers.<\/jats:p>","DOI":"10.3389\/fped.2020.551170","type":"journal-article","created":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T01:47:48Z","timestamp":1609811268000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":29,"title":["Hematopoietic Cell Transplantation for Sickle Cell Disease"],"prefix":"10.3389","volume":"8","author":[{"given":"Lakshmanan","family":"Krishnamurti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,1,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"18010","DOI":"10.1038\/nrdp.2018.10","article-title":"Sickle cell disease","volume":"4","author":"Kato","year":"2018","journal-title":"Nat Rev Dis Primers."},{"key":"B2","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/pbc.24176","article-title":"Health-related quality of life in sickle cell disease: past, present, and future","volume":"59","author":"Panepinto","year":"2012","journal-title":"Pediatr Blood Cancer."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1056\/NEJM199406093302303","article-title":"Mortality in sickle cell disease. Life expectancy and risk factors for early death","volume":"330","author":"Platt","year":"1994","journal-title":"N Engl J Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1182\/blood-2018-10-880575","article-title":"Decreased median survival of adults with sickle cell disease after adjusting for left truncation bias: a pooled analysis","volume":"133","author":"DeBaun","year":"2019","journal-title":"Blood."},{"key":"B5","doi-asserted-by":"publisher","first-page":"S512","DOI":"10.1016\/j.amepre.2009.12.022","volume":"38","year":"2010","journal-title":"Am J Prev Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/phar.2329","article-title":"Systematic review of l-glutamine for prevention of vaso-occlusive pain crisis in patients with sickle cell disease","volume":"39","author":"Cieri-Hutcherson","year":"2019","journal-title":"Pharmacotherapy."},{"key":"B7","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40265-020-01262-7","article-title":"Voxelotor: first approval","volume":"80","author":"Blair","year":"2020","journal-title":"Drugs"},{"key":"B8","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s40265-019-01254-2","article-title":"Crizanlizumab: first approval","volume":"80","author":"Blair","year":"2020","journal-title":"Drugs"},{"key":"B9","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1056\/NEJM199608083350601","article-title":"Bone marrow transplantation for sickle cell disease","volume":"335","author":"Walters","year":"1996","journal-title":"N Engl J Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1002\/ajh.24183","article-title":"Successful matched sibling donor marrow transplantation following reduced intensity conditioning in children with hemoglobinopathies","volume":"90","author":"King","year":"2015","journal-title":"Am J Hematol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1182\/blood-2007-03-079665","article-title":"Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease","volume":"110","author":"Bernaudin","year":"2007","journal-title":"Blood."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1182\/blood-2016-10-745711","article-title":"Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation","volume":"129","author":"Gluckman","year":"2017","journal-title":"Blood."},{"key":"B13","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1002\/ajh.25401","article-title":"Bone marrow transplantation for adolescents and young adults with sickle cell disease: results of a prospective multicenter pilot study","volume":"94","author":"Krishnamurti","year":"2019","journal-title":"Am J Hematol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1182\/blood-2016-05-715870","article-title":"A trial of unrelated donor marrow transplantation for children with severe sickle cell disease","volume":"128","author":"Shenoy","year":"2016","journal-title":"Blood."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1016\/j.bbmt.2017.05.027","article-title":"Unrelated umbilical cord blood transplantation for sickle cell disease following reduced-intensity conditioning: results of a phase I trial","volume":"23","author":"Abraham","year":"2017","journal-title":"Biol Blood Marrow Transplant."},{"key":"B16","doi-asserted-by":"publisher","first-page":"4285","DOI":"10.1182\/blood-2012-07-438408","article-title":"HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease","volume":"120","author":"Bolanos-Meade","year":"2012","journal-title":"Blood."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1016\/j.bbmt.2018.03.031","article-title":"Haploidentical peripheral blood stem cell transplantation demonstrates stable engraftment in adults with sickle cell disease","volume":"24","author":"Saraf","year":"2018","journal-title":"Biol Blood Marrow Transplant."},{"key":"B18","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/jama.2014.7192","article-title":"Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype","volume":"312","author":"Hsieh","year":"2014","journal-title":"JAMA."},{"key":"B19","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1182\/bloodadvances.2016002972","article-title":"Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT","volume":"1","author":"Fitzhugh","year":"2017","journal-title":"Blood Adv."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.bbmt.2019.02.011","article-title":"Nonmyeloablative matched sibling donor hematopoietic cell transplantation in children and adolescents with sickle cell disease","volume":"25","author":"Guilcher","year":"","journal-title":"Biol Blood Marrow Transplant"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/j.bbmt.2018.11.027","article-title":"Haploidentical bone marrow transplantation with post-transplantation cyclophosphamide plus thiotepa improves donor engraftment in patients with sickle cell anemia: results of an international learning collaborative","volume":"25","author":"de la Fuente","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e585","DOI":"10.1016\/S2352-3026(19)30154-1","article-title":"Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study","volume":"6","author":"Eapen","year":"2019","journal-title":"Lancet Haematol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/S0140-6736(12)61229-X","article-title":"Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates","volume":"381","author":"Piel","year":"2013","journal-title":"Lancet."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e1001484","DOI":"10.1371\/journal.pmed.1001484","article-title":"Global burden of sickle cell anaemia in children under five, 2010-2050: modelling based on demographics, excess mortality, and interventions","volume":"10","author":"Piel","year":"2013","journal-title":"PLoS Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.ymthe.2019.09.020","article-title":"Improved titer and gene transfer by lentiviral vectors using novel, small beta-globin locus control region elements","volume":"28","author":"Morgan","year":"2020","journal-title":"Mol Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/s41591-019-0401-y","article-title":"Highly efficient therapeutic gene editing of human hematopoietic stem cells","volume":"25","author":"Wu","year":"2019","journal-title":"Nat Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3389\/fped.2019.00443","article-title":"Autologous stem-cell-based gene therapy for inherited disorders: state of the art and perspectives","volume":"7","author":"Staal","year":"2019","journal-title":"Front Pediatr."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1016\/S2352-3026(19)30031-6","article-title":"Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial","volume":"6","author":"Bolanos-Meade","year":"2019","journal-title":"Lancet Haematol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"94","DOI":"10.7326\/0003-4819-148-2-200801150-00004","article-title":"Daily assessment of pain in adults with sickle cell disease","volume":"148","author":"Smith","year":"2008","journal-title":"Ann Int Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jpain.2018.07.006","article-title":"Prevalence and profile of high-impact chronic pain in the United States","volume":"20","author":"Pitcher","year":"2019","journal-title":"J Pain"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.jpain.2016.06.009","article-title":"United States national pain strategy for population research: concepts, definitions, pilot data","volume":"17","author":"Von Korff","year":"2016","journal-title":"J Pain."},{"key":"B32","doi-asserted-by":"publisher","first-page":"811","DOI":"10.3324\/haematol.2013.099747","article-title":"Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel","volume":"99","author":"Angelucci","year":"2014","journal-title":"Haematologica."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e543","DOI":"10.3324\/haematol.2019.216788","article-title":"Risk factors and outcomes according to age at transplantation with an HLA-identical sibling for sickle cell disease","volume":"104","author":"Cappelli","year":"2019","journal-title":"Haematologica"},{"key":"B34","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jpeds.2009.06.060","article-title":"Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial","volume":"156","author":"Ware","year":"2010","journal-title":"J Pediatr."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1182\/blood-2010-04-278747","article-title":"Biomarkers of splenic function in infants with sickle cell anemia: baseline data from the BABY HUG Trial","volume":"117","author":"Rogers","year":"2011","journal-title":"Blood."},{"key":"B36","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/j.1365-2141.2009.07753.x","article-title":"Silent infarcts in young children with sickle cell disease","volume":"146","author":"Kwiatkowski","year":"2009","journal-title":"Br J Haematol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1212\/WNL.56.8.1109","article-title":"Poor school and cognitive functioning with silent cerebral infarcts and sickle cell disease","volume":"56","author":"Schatz","year":"2001","journal-title":"Neurology."},{"key":"B38","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/j.1365-2141.2011.08598.x","article-title":"Milestones in umbilical cord blood transplantation","volume":"154","author":"Gluckman","year":"2011","journal-title":"Br J Haematol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1182\/blood-2013-03-489112","article-title":"Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling","volume":"122","author":"Locatelli","year":"2013","journal-title":"Blood."},{"key":"B40","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/bmt.2016.328","article-title":"Recipient and donor age impact the risk of developing chronic GvHD in children after allogeneic hematopoietic transplant","volume":"52","author":"Watkins","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"B41","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1182\/blood-2010-08-302109","article-title":"Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria","volume":"117","author":"Flowers","year":"2011","journal-title":"Blood."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.bbmt.2013.03.018","article-title":"Clinical guide to ABO-incompatible allogeneic stem cell transplantation","volume":"19","author":"Booth","year":"2013","journal-title":"Biol Blood Marrow Transplant."},{"key":"B43","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/petr.12552","article-title":"Is ABO mismatch another risk factor for allogeneic hematopoietic stem cell transplantation in pediatric thalassemic patients?","volume":"19","author":"Atay","year":"2015","journal-title":"Pediatr Transplant."},{"key":"B44","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.bbmt.2014.12.036","article-title":"ABO mismatch is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation","volume":"21","author":"Logan","year":"2015","journal-title":"Biol Blood Marrow Transplant."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.bbmt.2013.04.004","article-title":"Efficacy and long-term outcome of treatment for pure red cell aplasia after allogeneic stem cell transplantation from major ABO-incompatible donors","volume":"19","author":"Hirokawa","year":"2013","journal-title":"Biol Blood Marrow Transplant."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.bbmt.2017.11.018","article-title":"Experiences and decision making in hematopoietic stem cell transplant in sickle cell disease: patients' and caregivers' perspectives","volume":"24","author":"Khemani","year":"2018","journal-title":"Biol Blood Marrow Transplant."},{"key":"B47","doi-asserted-by":"publisher","first-page":"e0178413","DOI":"10.1371\/journal.pone.0178413","article-title":"Proponent or collaborative: Physician perspectives and approaches to disease modifying therapies in sickle cell disease","volume":"12","author":"Bakshi","year":"2017","journal-title":"PLoS ONE."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1002\/pbc.25446","article-title":"Current attitudes of parents and patients toward hematopoietic stem cell transplantation for sickle cell anemia","volume":"62","author":"Meier","year":"2015","journal-title":"Pediatr Blood Cancer."},{"key":"B49","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.bbmt.2017.08.034","article-title":"Ethical challenges in hematopoietic cell transplantation for sickle cell disease","volume":"24","author":"Nickel","year":"2018","journal-title":"Biol Blood Marrow Transplant."},{"key":"B50","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1182\/blood-2014-05-575209","article-title":"The ethics of a proposed study of hematopoietic stem cell transplant for children with less severe sickle cell disease","volume":"124","author":"Nickel","year":"2014","journal-title":"Blood."},{"key":"B51","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.wneu.2018.11.157","article-title":"Surgical revascularization for pediatric patients with sickle cell disease and moyamoya disease in the prevention of ischemic strokes: a single-center case series and a systematic review","volume":"123","author":"Aguilar-Salinas","year":"2019","journal-title":"World Neurosurg."},{"key":"B52","doi-asserted-by":"publisher","first-page":"e174","DOI":"10.1016\/j.bbmt.2019.01.008","article-title":"Functional and radiologic assessment of the brain after reduced-intensity unrelated donor transplantation for severe sickle cell disease-blood and marrow transplant clinical trials network #0601","volume":"25","author":"King","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B53","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/03630269.2016.1224766","article-title":"Renal failure in sickle cell disease: prevalence, predictors of disease, mortality and effect on length of hospital stay","volume":"40","author":"Yeruva","year":"2016","journal-title":"Hemoglobin."},{"key":"B54","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2215\/CJN.03940415","article-title":"Kidney disease among patients with sickle cell disease, hemoglobin SS and SC","volume":"11","author":"Drawz","year":"2016","journal-title":"Clin J Am Soc Nephrol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1002\/pbc.25904","article-title":"Improved splenic function after hematopoietic stem cell transplant for sickle cell disease","volume":"63","author":"Nickel","year":"2016","journal-title":"Pediatr Blood Cancer."},{"key":"B56","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.bbmt.2017.08.039","article-title":"HLA haploidentical stem cell transplant with pretransplant immunosuppression for patients with sickle cell disease","volume":"24","author":"Pawlowska","year":"2018","journal-title":"Biol Blood Marrow Transplant."},{"key":"B57","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s41409-017-0062-8","article-title":"The European Society for Blood and Marrow Transplantation (EBMT) consensus guidelines for the detection and treatment of Donor-specific Anti-HLA Antibodies (DSA) in haploidentical hematopoietic cell transplantation","volume":"53","author":"Ciurea","year":"2018","journal-title":"Bone Marrow Transplant."},{"key":"B58","doi-asserted-by":"publisher","first-page":"e553","DOI":"10.1016\/S2352-3026(17)30196-5","article-title":"Immunohaematological complications in patients with sickle cell disease after haemopoietic progenitor cell transplantation: a prospective, single-centre, observational study","volume":"4","author":"Allen","year":"2017","journal-title":"Lancet Haematol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.bbmt.2012.01.019","article-title":"Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN)","volume":"18","author":"Kamani","year":"2012","journal-title":"Biol Blood Marrow Transplant."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1007\/s00277-017-3030-x","article-title":"Reduced toxicity, myeloablative HLA-haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for sickle cell disease","volume":"96","author":"Wiebking","year":"2017","journal-title":"Ann Hematol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1182\/blood-2014-02-514778","article-title":"Conditioning regimens for hematopoietic cell transplantation: one size does not fit all","volume":"124","author":"Gyurkocza","year":"2014","journal-title":"Blood."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant."},{"key":"B63","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.bbmt.2015.01.015","article-title":"Using fludarabine to reduce exposure to alkylating agents in children with sickle cell disease receiving busulfan, cyclophosphamide, and antithymocyte globulin transplant conditioning: results of a dose de-escalation trial","volume":"21","author":"Horan","year":"2015","journal-title":"Biol Blood Marrow Transplant."},{"key":"B64","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1111\/bjh.13352","article-title":"Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickle cell disease","volume":"169","author":"Strocchio","year":"2015","journal-title":"Br J Haematol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1083-8791(03)00192-7","article-title":"Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia","volume":"9","author":"Iannone","year":"2003","journal-title":"Biol Blood Marrow Transplant."},{"key":"B66","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/sj.bmt.1704745","article-title":"Hematopoietic stem cell transplantation for multiply transfused patients with sickle cell disease and thalassemia after low-dose total body irradiation, fludarabine, and rabbit anti-thymocyte globulin","volume":"35","author":"Horan","year":"2005","journal-title":"Bone Marrow Transplant."},{"key":"B67","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.bbmt.2015.08.036","article-title":"Nonmyeloablative stem cell transplantation with alemtuzumab\/low-dose irradiation to cure and improve the quality of life of adults with sickle cell disease","volume":"22","author":"Saraf","year":"2016","journal-title":"Biol Blood Marrow Transplant."},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.4592.459s2","article-title":"Alemtuzumab\/low dose tbi conditioning facilitates stable long-term donor hematopoietic cell engraftment from sibling donors in children with sickle cell disease","author":"Guilcher","year":"2017","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1182\/bloodadvances.2017005462","article-title":"Alternative donor hematopoietic stem cell transplantation for sickle cell disease","volume":"1","author":"Gilman","year":"2017","journal-title":"Blood Adv."},{"key":"B70","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/bmt.2017.49","article-title":"Haploidentical stem cell transplantation with CD3(+)-\/CD19(+)- depleted peripheral stem cells for patients with advanced stage sickle cell disease and no alternative donor: results of a pilot study","volume":"52","author":"Foell","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"B71","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1182\/bloodadvances.2017012005","article-title":"Haploidentical HSCT for hemoglobinopathies: improved outcomes with TCRalphabeta(+)\/CD19(+)-depleted grafts","volume":"2","author":"Gaziev","year":"2018","journal-title":"Blood Adv."},{"key":"B72","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.hemonc.2019.12.006","article-title":"Alternative donor: alphass\/CD19 T-cell-depleted haploidentical hematopoietic stem cell transplantation for sickle cell disease","volume":"13","author":"Foell","year":"2020","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"B73","doi-asserted-by":"publisher","first-page":"3894","DOI":"10.1182\/bloodadvances.2020002236","article-title":"Abatacept is effective as GVHD prophylaxis in unrelated donor stem cell transplantation for children with severe sickle cell disease","volume":"4","author":"Ngwube","year":"2020","journal-title":"Blood Adv."},{"key":"B74","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/bmt.2012.239","article-title":"Graft failure in the modern era of allogeneic hematopoietic SCT","volume":"48","author":"Olsson","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"B75","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1182\/blood-2012-03-417758","article-title":"Evaluation of HLA matching in unrelated hematopoietic stem cell transplantation for nonmalignant disorders","volume":"120","author":"Horan","year":"2012","journal-title":"Blood."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.bbmt.2011.01.012","article-title":"Umbilical cord blood transplantation for children with thalassemia and sickle cell disease","volume":"17","author":"Ruggeri","year":"2011","journal-title":"Biol Blood Marrow Transplant."},{"key":"B77","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1053\/bbmt.2001.v7.pm11787529","article-title":"Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia","volume":"7","author":"Walters","year":"2001","journal-title":"Biol Blood Marrow Transplant."},{"key":"B78","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1016\/j.bbmt.2017.08.038","article-title":"Relationship between mixed donor-recipient chimerism and disease recurrence after hematopoietic cell transplantation for sickle cell disease","volume":"23","author":"Abraham","year":"2017","journal-title":"Biol Blood Marrow Transplant."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1182\/blood-2017-03-772392","article-title":"At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT","volume":"130","author":"Fitzhugh","year":"2017","journal-title":"Blood."},{"key":"B80","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/j.1365-2141.2007.06803.x","article-title":"Mixed haematopoietic chimerism for sickle cell disease prevents intravascular haemolysis","volume":"139","author":"Wu","year":"2007","journal-title":"Br J Haematol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1016\/j.bbmt.2008.08.016","article-title":"Stable long-term donor engraftment following reduced-intensity hematopoietic cell transplantation for sickle cell disease","volume":"14","author":"Krishnamurti","year":"2008","journal-title":"Biol Blood Marrow Transplant."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.bbmt.2018.04.002","article-title":"Late effects screening guidelines after hematopoietic cell transplantation (HCT) for hemoglobinopathy: consensus statement from the second pediatric blood and marrow transplant consortium international conference on late effects after pediatric HCT","volume":"24","author":"Shenoy","year":"2018","journal-title":"Biol Blood Marrow Transplant."},{"key":"B83","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1182\/blood.V85.4.879.bloodjournal854879","article-title":"Neurologic complications after allogeneic marrow transplantation for sickle cell anemia","volume":"85","author":"Walters","year":"1995","journal-title":"Blood."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/j.bbmt.2017.05.033","article-title":"Posterior reversible encephalopathy syndrome after hematopoietic cell transplantation in children with hemoglobinopathies","volume":"23","author":"Gaziev","year":"2017","journal-title":"Biol Blood Marrow Transplant."},{"key":"B85","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1002\/pbc.25932","article-title":"Neurological PRESentations in sickle cell patients are not always stroke: a review of posterior reversible encephalopathy syndrome in sickle cell disease","volume":"63","author":"Solh","year":"2016","journal-title":"Pediatr Blood Cancer."},{"key":"B86","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0002-9343(96)00407-X","article-title":"Natural history of blood pressure in sickle cell disease: risks for stroke and death associated with relative hypertension in sickle cell anemia","volume":"102","author":"Pegelow","year":"1997","journal-title":"Am J Med."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/S0140-6736(84)91556-3","article-title":"Association between cyclosporin neurotoxicity and hypomagnesaemia","volume":"2","author":"Thompson","year":"1984","journal-title":"Lancet."},{"key":"B88","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/00007890-198601000-00009","article-title":"Correlation of hypomagnesemia with the onset of cyclosporine-associated hypertension in marrow transplant patients","volume":"41","author":"June","year":"1986","journal-title":"Transplantation."},{"key":"B89","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.1182\/blood-2014-09-551564","article-title":"How I treat and manage strokes in sickle cell disease","volume":"125","author":"Kassim","year":"2015","journal-title":"Blood."},{"key":"B90","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1056\/NEJMoa035477","article-title":"Pulmonary hypertension as a risk factor for death in patients with sickle cell disease","volume":"350","author":"Gladwin","year":"2004","journal-title":"N Engl J Med."},{"key":"B91","doi-asserted-by":"publisher","first-page":"e99489","DOI":"10.1371\/journal.pone.0099489","article-title":"Risk factors for death in 632 patients with sickle cell disease in the United States and United Kingdom","volume":"9","author":"Gladwin","year":"2014","journal-title":"PLoS ONE."},{"key":"B92","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1001\/archpedi.1994.02170080026005","article-title":"Reference values and hematologic changes from birth to 5 years in patients with sickle cell disease. Cooperative study of sickle cell disease","volume":"148","author":"Brown","year":"1994","journal-title":"Arch Pediatr Adolesc Med."},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26713","article-title":"Invasive pneumococcal disease in children with sickle cell disease in the pneumococcal conjugate vaccine era","author":"Martin","year":"2018","journal-title":"Pediatr Blood Cancer."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant."},{"key":"B95","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/nyas.13027","article-title":"Management of iron overload before, during, and after hematopoietic stem cell transplantation for thalassemia major","volume":"1368","author":"Angelucci","year":"2016","journal-title":"Ann N Y Acad Sci."},{"key":"B96","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1182\/blood.V90.3.994.994_994_998","article-title":"Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation. Italian Cooperative Group for Phlebotomy Treatment of Transplanted Thalassemia Patients","volume":"90","author":"Angelucci","year":"1997","journal-title":"Blood."},{"key":"B97","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/j.1365-2141.1995.tb08426.x","article-title":"Desferrioxamine therapy accelerates clearance of iron deposits after bone marrow transplantation for thalassaemia","volume":"89","author":"Giardini","year":"1995","journal-title":"Br J Haematol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/S0140-6736(94)91559-8","article-title":"Compliance with iron-chelation treatment after bone marrow transplantation","volume":"343","author":"Schettini","year":"1994","journal-title":"Lancet."},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26566","article-title":"Double trouble: complement-mediated thrombotic microangiopathy in patients with hemoglobinopathies after stem cell transplantation","author":"Jodele","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26503","article-title":"Severe transplant-associated thrombotic microangiopathy in patients with hemoglobinopathies","author":"Abusin","year":"2017","journal-title":"Pediatr Blood Cancer."},{"key":"B101","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1056\/NEJM198409203111207","article-title":"Bone-marrow transplantation in a patient with sickle-cell anemia","volume":"311","author":"Johnson","year":"1984","journal-title":"N Engl J Med"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1182\/blood.V95.6.1918","article-title":"Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease","volume":"95","author":"Walters","year":"2000","journal-title":"Blood."},{"key":"B103","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/s41409-018-0111-y","article-title":"Allogenic peripheral stem cell transplantation from HLA-matched related donors for adult sickle cell disease: remarkable outcomes from a single-center trial","volume":"53","author":"Ozdogu","year":"2018","journal-title":"Bone Marrow Transplant."},{"key":"B104","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1001\/jama.2018.20059","article-title":"Association of matched sibling donor hematopoietic stem cell transplantation with transcranial Doppler velocities in children with sickle cell anemia","volume":"321","author":"Bernaudin","year":"2019","journal-title":"JAMA."},{"key":"B105","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.bbmt.2009.10.005","article-title":"Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease","volume":"16","author":"Walters","year":"2010","journal-title":"Biol Blood Marrow Transplant."},{"key":"B106","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.bbmt.2014.12.007","article-title":"Health-related quality of life after allogeneic hematopoietic stem cell transplantation for sickle cell disease","volume":"21","author":"Bhatia","year":"2015","journal-title":"Biol Blood Marrow Transplant."},{"key":"B107","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.bbmt.2013.02.010","article-title":"Long-term outcome and evaluation of organ function in pediatric patients undergoing haploidentical and matched related hematopoietic cell transplantation for sickle cell disease","volume":"19","author":"Dallas","year":"2013","journal-title":"Biol Blood Marrow Transplant."},{"key":"B108","doi-asserted-by":"publisher","first-page":"e0229710","DOI":"10.1371\/journal.pone.0229710","article-title":"Improved health care utilization and costs in transplanted versus non-transplanted adults with sickle cell disease","volume":"15","author":"Saraf","year":"2020","journal-title":"PLoS ONE."},{"key":"B109","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/bjh.15169","article-title":"Pain and opioid use after reversal of sickle cell disease following HLA-matched sibling haematopoietic stem cell transplant","volume":"184","author":"Darbari","year":"2019","journal-title":"Br J Haematol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1182\/blood.2020005687","article-title":"Risk score to predict event-free survival after hematopoietic cell transplant for sickle cell disease","volume":"136","author":"Brazauskas","year":"2020","journal-title":"Blood."},{"key":"B111","first-page":"100","article-title":"Barriers to bone marrow transplantation for sickle cell anemia","volume":"2","author":"Walters","year":"1996","journal-title":"Biol Blood Marrow Transplant."},{"key":"B112","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1056\/NEJMsa1311707","article-title":"HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry","volume":"371","author":"Gragert","year":"2014","journal-title":"N Engl J Med."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1002\/pbc.25439","article-title":"Allogeneic donor availability for hematopoietic stem cell transplantation in children with sickle cell disease","volume":"62","author":"Justus","year":"2015","journal-title":"Pediatr Blood Cancer."},{"key":"B114","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.stem.2015.10.004","article-title":"Phase I\/II trial of StemRegenin-1 expanded umbilical cord blood hematopoietic stem cells supports testing as a stand-alone graft","volume":"18","author":"Wagner","year":"2016","journal-title":"Cell Stem Cell."},{"key":"B115","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1126\/science.110.2865.543","article-title":"Sickle cell anemia a molecular disease","volume":"110","author":"Pauling","year":"1949","journal-title":"Science."},{"key":"B116","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1056\/NEJMoa1609677","article-title":"Gene therapy in a patient with sickle cell disease","volume":"376","author":"Ribeil","year":"2017","journal-title":"N Engl J Med."},{"key":"B117","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/5584_2018_331","article-title":"CRISPR\/Cas9 for sickle cell disease: applications, future possibilities, and challenges","volume":"1144","author":"Demirci","year":"2019","journal-title":"Adv Exp Med Biol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41573-019-0020-9","article-title":"Gene therapy targeting haematopoietic stem cells for inherited diseases: progress and challenges","volume":"18","author":"Cavazzana","year":"2019","journal-title":"Nat Rev Drug Discov."},{"key":"B119","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1089\/hum.2018.061","article-title":"Gene therapy for sickle cell disease: a lentiviral vector comparison study","volume":"29","author":"Urbinati","year":"2018","journal-title":"Hum Gene Ther."},{"key":"B120","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.bcmd.2017.12.001","article-title":"Gene therapy and gene editing strategies for hemoglobinopathies","volume":"70","author":"Lidonnici","year":"2018","journal-title":"Blood Cells Mol Dis."},{"key":"B121","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1053\/j.seminhematol.2018.04.014","article-title":"Genetic therapies for sickle cell disease","volume":"55","author":"Esrick","year":"2018","journal-title":"Semin Hematol."},{"key":"B122","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.exphem.2019.08.002","article-title":"CTLA4Ig-based reduced intensity conditioning and donor lymphocyte infusions for haploidentical transplantation in refractory aggressive B-cell lymphoma relapsing after an autograft: Early results from a pilot study","volume":"77","author":"Jaiswal","year":"2019","journal-title":"Exp Hematol."},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2019.05.018","article-title":"Antibody conditioning enables MHC-mismatched hematopoietic stem cell transplants and organ graft tolerance","author":"George","year":"2019","journal-title":"Cell Stem Cell."},{"key":"B124","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.bbmt.2019.11.007","article-title":"Radioimmunotherapy in combination with reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in patients with advanced multiple myeloma","volume":"26","author":"Fasslrinner","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B125","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1056\/NEJMe2003331","article-title":"N Engl J Med","volume":"382","author":"Chao","year":"2020"},{"key":"B126","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1080\/13543784.2020.1757069","article-title":"Ruxolitinib: a potential treatment for corticosteroid refractory acute graft-versus-host disease","volume":"29","author":"Abedin","year":"2020","journal-title":"Expert Opin Investig Drugs."},{"key":"B127","doi-asserted-by":"publisher","first-page":"2040620719891358","DOI":"10.1177\/2040620719891358","article-title":"Biomarkers in acute graft-versus-host disease: new insights","volume":"10","author":"Srinagesh","year":"2019","journal-title":"Ther Adv Hematol."},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.3271.3271","article-title":"Development of a multi-center cohort to evaluate long-term outcomes and late effects following hematopoietic cell transplantation for sickle cell disease: a STAR initiative","author":"Stenger","year":"2017","journal-title":"Blood"},{"key":"B129","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.bbmt.2017.01.009","article-title":"Current results and future research priorities in late effects after hematopoietic stem cell transplantation for children with sickle cell disease and thalassemia: a consensus statement from the second pediatric blood and marrow transplant consortium international conference on late effects after pediatric hematopoietic stem cell transplantation","volume":"23","author":"Shenoy","year":"2017","journal-title":"Biol Blood Marrow Transplant."},{"key":"B130","doi-asserted-by":"publisher","first-page":"3868","DOI":"10.1172\/JCI87885","article-title":"Lineage-specific BCL11A knockdown circumvents toxicities and reverses sickle phenotype","volume":"126","author":"Brendel","year":"2016","journal-title":"J Clin Invest."},{"key":"B131","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/j.jcyt.2017.06.002","article-title":"Preclinical studies for a phase 1 clinical trial of autologous hematopoietic stem cell gene therapy for sickle cell disease","volume":"19","author":"Urbinati","year":"2017","journal-title":"Cytotherapy."},{"key":"B132","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.3324\/haematol.2017.169581","article-title":"Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases","volume":"102","author":"Arnold","year":"2017","journal-title":"Haematologica."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2020.551170\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T01:47:52Z","timestamp":1609811272000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2020.551170\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,5]]},"references-count":132,"alternative-id":["10.3389\/fped.2020.551170"],"URL":"https:\/\/doi.org\/10.3389\/fped.2020.551170","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,5]]},"article-number":"551170"}}